Table 1.
Immunohistochemistry (IHC) of breast tumor marker expression distribution: EPIC-Heidelberg nested case-control study
| Marker | Antibody | Dilution | Defined as: | N = 287 | % | |
|---|---|---|---|---|---|---|
| CYP27A1 | Abcam | Positive = moderate or strong (2 or 3) intensity in cytoplasm; otherwise negative | – | 201 | 73.6 | |
| (EPR7529) | 1:50 | + | 72 | 26.4 | ||
| CYP7B1 | Abcam (ab19043) | 1:500 | Positive = moderate or strong (2 or 3) intensity in cytoplasm of ≥ 10% of cells; otherwise negative | – | 157 | 64.6 |
| + | 86 | 35.4 | ||||
| LXR-β | Abcam (ab24361) | 1:25 | Positive = moderate or strong (2 or 3) intensity in nucleus of ≥ 10% of cells; otherwise negative | – | 123 | 42.9 |
| + | 164 | 57.1 | ||||
| ERβ | Serotec (PPG5/10) | 1:500 | Positive = moderate or strong intensity (2 or 3) nuclear staining in > 50% tumor cells; otherwise negative | – | 84 | 29.3 |
| + | 203 | 70.7 |
Missing due to inconclusive staining: 44 for CYP7B1, 14 for CYP27A1
287 matched pairs of cases and controls have been used for the analysis (243 breast cancer cases have no tumor blocks available)